Sign in

    Rohit Bhasin

    Research Analyst at Morgan Stanley

    Rohit Bhasin is an Equity Research Associate at Morgan Stanley & Co. LLC, specializing in coverage of health and consumer services companies, including names such as Fractyl Health Inc. and Mirum Pharmaceuticals. Since joining Morgan Stanley in August 2023, Bhasin has been actively involved in earnings call analysis and company research, contributing to insightful investment discussions and supporting major institutional clients. Previously, he held research roles at Needham & Co. LLC and led pharmacy operations at AgeWell New York LLC, reflecting a strong background in both finance and healthcare. Dr. Bhasin holds a doctorate from St. John's University, an MBA from Baruch College, and is registered through FINRA, underscoring his robust professional credentials.

    Rohit Bhasin's questions to FRACTYL HEALTH (GUTS) leadership

    Rohit Bhasin's questions to FRACTYL HEALTH (GUTS) leadership • Q2 2025

    Question

    Rohit Bhasin, on behalf of Mike Ulz at Morgan Stanley, asked about new learnings from the evolving GLP-1 market and the potential impact on the outlook for Revita and Rejuva.

    Answer

    Harith Rajagopalan, Co-Founder, CEO & Director, highlighted two key trends: patients are now frequently asking when they can stop GLP-1 medications, and real-world data is showing lower effectiveness for these drugs than seen in clinical trials. He explained that these trends underscore the significant unmet need for a durable, disease-modifying therapy like Revita.

    Ask Fintool Equity Research AI

    Rohit Bhasin's questions to Mirum Pharmaceuticals (MIRM) leadership

    Rohit Bhasin's questions to Mirum Pharmaceuticals (MIRM) leadership • Q4 2024

    Question

    Rohit Bhasin, on for Mike Ulz, asked about the LIVMARLI patient mix between Alagille syndrome and PFIC in Q4, its expected evolution in 2025, and the status of expanded access PFIC patients.

    Answer

    CEO Chris Peetz confirmed that all U.S. expanded access PFIC patients were converted to commercial product by Q3 2024. He noted that while Alagille syndrome patients are the majority, PFIC patient starts have significantly increased since Q3, becoming a substantial contributor to new patient growth.

    Ask Fintool Equity Research AI